Use of nanoemulsion for co-delivery of silibinin and cabazitaxel for prostate cancer treatment
These findings establish NE-SIL/CBX as a promising platform for PCa treatment, offering improved therapeutic index and reduced systemic toxicity. Future clinical investigations could validate its potential for precision oncology applications.
Authors
- Sitah Alharthi (ORCID: https://orcid.org/0000-0003-0031-5654)
- Hasan Ebrahimi Shahmabadi (ORCID: https://orcid.org/0000-0001-5222-3829)
- Bandar Almutairy
- Seyed Ebrahim Alavi (ORCID: https://orcid.org/0000-0003-4009-4921)
Institutions
- Shaqra University (SA)
- Rafsanjan University of Medical Sciences (IR)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1080/03639045.2025.2552392
- Citations
- 3
- Primary Topic
- Silymarin and Mushroom Poisoning
- Type
- article
- Field-Weighted Citation Impact
- 4.56